|
|
|
|
|
Levobunolol
drug data and news
Levobunolol drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Levobunolol | ||
| Brand Names/Synonyms | Akbeta; Betagan; Bunolol Levobunolol; CCRIS 4375; LEVOBUNOLOL; Levobunolol; Levobunolol Hcl; Levobunololum [Inn-Latin] | ||
| Indication | For lowering intraocular pressure and may be used in patients with chronic open-angle glaucoma or ocular hypertension | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Levobunolol is an ophthalmic beta-blocker, equally effective at β(1)- and β(2)-receptor sites. The levorotatory isomer of bunolol, levobunolol is used for the treatment of IOP due to open-angle glaucoma or ocular hypertension. | ||
| Mechanism Of Action | Levobunolol's mechanism of action in reducing IOP is believed to be due to a reduction of the production of aqueous humor via inhibition of adrenergically driven processes within the ciliary processes. | ||
| Levobunolol News (When available) |
Glaucoma treatment has options Apr 23, 2006 | ||
| Dosage Forms | Liquifilm sterile ophthalmic solution | ||
| Drug_Category | Sympatholytics; EENT Drugs; ATC:S01ED03 | ||
| Absorption | 80% | ||
| Interactions |
Interactions for Levobunolol: Although BETAGAN used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with BETAGAN and epinephrine may occur. Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope or postural hypotension. Patients receiving beta-adrenergic blocking agents along with either oral or intravenous calcium antagonists should be monitored for possible atrioventricular conduction disturbances, left ventricular failure and hypotension. In patients with impaired cardiac function, simultaneous use should be avoided altogether. The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects on prolonging atrioventricular conduction time. Phenothiazine-related compounds and beta-adrenergic blocking agents may have additive hypotensite effects due to the inhibition of each otherís metabolism. | ||
| Toxicity | bradycardia, hypotension, bronchospasm, and acute cardiac failure, LD50=700 mg/kg (orally in rat) | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 5-(2-hydroxy-3-tert-butylamino-propoxy)tetralin-1-one | ||
| Chemical Formula | C17H25NO3 | ||
| Molecular Weight | 291.385 g/mol | ||
| Smiles String | CC(C)(C)NCC(COC1=CC=CC2=C1CCCC2=O)O | ||
| Melting Point | 209-211°C | ||
| Water Solubility | Not Available | ||
| State | Solid | ||
| LogP/Hphobicity | 2.276 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Hepatic | ||
| Half Life | 20 hours | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Levobunolol.html http://www.rxlist.com/cgi/generic/levobunolol.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00165 | ||
| CAS Registry Number | 47141-42-4 | ||
| KEGG Compound ID | C07914 | ||
| PubChem ID | SID:10116 | ||
| PharmGKB ID | Not Available | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2241575 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |